Akers Biosciences Announces Conference Call to Discuss FY 2016 Earnings
March 29 2017 - 7:45AM
Marketwired
THOROFARE, NJ-(Marketwired - Mar 29, 2017) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a
developer of rapid health information technologies, will hold a
conference call on Friday, March 31, 2017 at 08:00 a.m. Eastern
Time to discuss its earnings for the year ended December 31, 2016,
which will be published earlier that day. Management will be
available during a question-and-answer session.
To participate in the call from within the U.S., please dial
1-888-318-7451 approximately 10 minutes prior to the scheduled
start time. International callers should dial 1-719-325-2108. The
Conference ID is 7871664. Interested parties can also listen via a
live Internet webcast, which can be found at
http://public.viavid.com/index.php?id=123601.
A recording of the call will be available in the Investor Center
of the Company's website at
http://www.akersbio.com/investor-center. About Akers Biosciences,
Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking
StatementsStatements contained herein that are not based upon
current or historical fact are forward-looking in nature and
constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such forward-looking statements reflect the
Company's expectations about its future operating results,
performance and opportunities that involve substantial risks and
uncertainties. These statements include but are not limited to
statements regarding the intended terms of the offering, closing of
the offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848
8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel.
+1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave /
Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona
Henson
Tel. +44 (0)20 7830 9700
Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Oct 2023 to Oct 2024